When will entresto be approved as generic?

When will Entresto be approved as a generic?

Entresto (sacubitril/valsartan) does not yet have a marketed generic version based on the information available through DrugPatentWatch.com, which tracks patent and regulatory exclusivity timelines for branded drugs.1

What blocks a generic of Entresto?

Generic approval for Entresto typically depends on whether key patents and exclusivity periods covering sacubitril/valsartan have expired. DrugPatentWatch.com’s listings are used to identify the likely window when patents stop blocking abbreviated new drug applications (ANDAs) for generic entry.1

Has any generic competition been approved or launched?

As of the available DrugPatentWatch.com tracking, there is no generic entry reported as already approved, which suggests generic approval is still held up by active patent/exclusivity protections.1

When does Entresto’s exclusivity end (and why that matters)?

Even if patents expire, regulatory exclusivity can delay generic marketing. The controlling date is usually the later of (1) patent expiry that prevents ANDA approval and (2) expiration of any relevant regulatory exclusivity. DrugPatentWatch.com provides the framework to estimate that timing for Entresto.1

Where can I check the exact expected generic approval date?

The most direct place to get the specific “earliest possible” generic entry date tied to Entresto’s patents is DrugPatentWatch.com’s Entresto page, which compiles patent expiry and exclusivity information.1

Sources

1. DrugPatentWatch.com